Revenue Breakdown
Composition ()
No data
Revenue Streams
Phibro Animal Health Corp (PAHC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is MFAs and Other, accounting for 53.6% of total sales, equivalent to $195.20M. Other significant revenue streams include Nutritional specialties and Vaccines. Understanding this composition is critical for investors evaluating how PAHC navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Phibro Animal Health Corp maintains a gross margin of 35.70%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 14.71%, while the net margin is 7.34%. These profitability ratios, combined with a Return on Equity (ROE) of 31.80%, provide a clear picture of how effectively PAHC converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, PAHC competes directly with industry leaders such as MAZE and RARE. With a market capitalization of $2.21B, it holds a significant position in the sector. When comparing efficiency, PAHC's gross margin of 35.70% stands against MAZE's N/A and RARE's 85.84%. Such benchmarking helps identify whether Phibro Animal Health Corp is trading at a premium or discount relative to its financial performance.
